Valneva Phase 2 Trial: Positive Safety Results
Okay, here’s a breakdown of the provided citations, formatted for clarity. I’ve separated them adn included the key information:
1. Pfizer Q2 2025 Earnings Conference Call Prepared Remarks
Source: Pfizer
Date: Q2 2025 (document date – likely released before Q2 2025)
Link:
2.Pfizer and Valneva Initiate Phase 3 Lyme Disease Vaccine Study
Source: Valneva (via GlobeNewswire press release)
Date: August 2022
Link: https://valneva.com/press-release/pfizer-and-valneva-initiate-phase-3-study-of-lyme-disease-vaccine-candidate-vla15/
Access Date: august 2023
3. Stanek et al. (2012)
Authors: Stanek et al.
Date: 2012
Journal: The Lancet
Volume/Issue/Pages: 379: 461-473
4. Centers for Disease Control and Prevention – lyme disease Statistics
Source: Centers for Disease Control and Prevention (CDC)
Topic: lyme Disease Statistics (Human Cases)
Date: January 2021
Link: https://www.cdc.gov/lyme/stats/humancases.html
Access Date: August 2024
5. Kugeler et al. (2021)
Authors: Kugeler KJ, et al.
Date: 2021
Journal: Emergency Infectious Disease
Volume/Issue: 27(2)
Title: Estimating the frequency of Lyme disease diagnoses-United States, 2010-2018.
6. Centers for Disease Control – Understanding Lyme & Tickborne Diseases
Source: Centers for Disease Control and Prevention (CDC)
Topic: Understanding lyme and Other Tickborne Diseases
Date: May 2022
Link: https://www.cdc.gov/lyme/resources/tickborne-diseases.html
Important Notes:
Access Dates: The “Accessed” dates indicate when the online sources were last checked. Information on websites can change, so this is critically important for verifying the information. GlobeNewswire: GlobeNewswire is a press release distribution service. The source of the information is Valneva, but it was distributed through globenewswire.
Future Date: Citation 1 refers to Q2 2025, which is in the future as of today (November 21, 2023). This suggests the document was prepared before Q2 2025.
Let me know if you’d like me to do anything else with these citations (e.g.,